<DOC>
	<DOCNO>NCT01381497</DOCNO>
	<brief_summary>Migraine headache lead absenteeism restrict on-the-job productivity ( presenteeism ) employ migraine sufferer . Effective migraine treatment reduce migraine-associated productivity loss return migraineurs normal function within hour treatment . This study observational , multicenter , parallel-group study employ patient prescribe either combination product contain sumatriptan naproxen sodium ( SumaRT/Nap ) oral triptan monotherapy treat acute migraine attack . The study report result 4 migraine attack per patient . Eligible migraine attack define preceded 24-hour , headache-free period onset 2 hour prior start 4 hour end schedule work shift . Data collect time treatment hourly end attack end workday . To estimate baseline productivity , data collect 50 randomly select subject migraine-free workday . The primary objective study compare migraine-related , work productivity loss ( absenteeism presenteeism ) report patient treat SumaRT/Nap loss report patient treated triptan monotherapy . The null hypothesis difference observe number hour productivity lose patient treat workday migraine attack SumaRT/Nap patient treat migraine attack oral triptan alone . The alternative hypotheses patient either treatment group experience significantly few hour lose productivity associate migraine compare patient treatment group . The secondary objective study measure time treatment return patient-reported , normal functioning ; evaluate rescue medication use initial treatment ; measure total productivity loss follow treatment hourly time point ; estimate probability absenteeism migraine begin workday . The null hypothesis secondary endpoint difference observe result report patient treat SumaRT/Nap patient treat triptan monotherapy . The alternative hypothesis either treatment superior endpoint .</brief_summary>
	<brief_title>Impact Migraine Work Productivity Patients Treated With Combination Product Containing Sumatriptan Naproxen Sodium Triptan Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Age 18 65 Currently treat migraine attack SumaRT/Nap oral triptan monotherapy Have diagnosis migraine without aura ( 2004 International Classification Headache Disorders ( ICHD ) II criterion ) Have least 2 8 migraine attack per month previous 2 month Score 56 high Headache Impact Test 6 ( HIT6 ) Be actively employeed least 30 hour per week work day time shift ( begin 6 11 AM ) Have experience treat disable migraine work place month prior screen Be willing treat mild , moderate , severe migraine work place usual medication ( SumaRT/Nap oral triptan alone ) Be willing adhere protocol requirement include , limited , hourly phone call Interactive VoiceActivated Recording System ( IVRS ) clinic visit Have active cell phone plan sufficient monthly minute study period collect data via IVRS willing provide cell phone number study team Consent phone IVRS onset migraine attack prior workday receive 8 phone call ( 1 2 minute ) workday . Be able distinguish migraine attack headache type Be able hear , understand , verbally answer question IVRS English Be willing able give write informed consent participate study Female subject childbearing potential must use reliable method birth control agree upon investigator male partner physiologically surgically sterile . Any subject take oral contraceptive must stable regimen least two month prior screen . Subject often treat migraine attack combination single entity triptan medication Has 15 headache day per month total , retinal ( ICHII 1.4 ) , basilar ( ICHDII 1.26 ) hemiplegic migraine ( ICHDII 1.25 ) , secondary headache Has HIT6 score 56 screen Works even night shift work home Has hypersensitivity , allergy , intolerance , contraindication triptan nonsteriodal antiinflammatory ( NSAID ) drug include aspirin sumatriptan naproxen preparation . Has nasal polyp asthma Is currently take , take 2 week prior screen , migraine prophylactic medication contain methylsergide dihydroergotamine ; takign medication stablized ( i.e . change dose within previous two month ) intermittant migraine prophylaxis comorbid condition stablized Has recent history regular use opioids barbituates treatment migraine headache and/or nonmigraine pain . Regular use define average 4 day per month month last 3 month Has take plan take monoamine oxidase ( MAOI ) inhibitor include herbal preparation contain St. John 's Wort ( Hypericum perforatum ) anytime within 2 week prior screen 2 week post final study treatment Is pregnant , actively try become pregnant , breast feeding Has evidence alcohol substance abuse within last year concurrent medical psychiatric condition , investigator 's judgement , likely interfere study conduct , subject cooperation , evaluation interpretation study result , otherwise contraindicate participation clinical trial Has participate investigational drug trial within previous 4 week plan participate another study time study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>presenteeism</keyword>
	<keyword>migraine disorder</keyword>
	<keyword>work productivity</keyword>
	<keyword>triptan</keyword>
	<keyword>sumatriptan naproxen sodium</keyword>
	<keyword>absenteeism</keyword>
</DOC>